Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M126Revenue $M0.1Net Margin (%)0Z-Score2.2
Enterprise Value $M86.0EPS $-0.1Operating Margin %0F-Score3
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)0Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %-2.6Quick Ratio46.5Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-2.5Current Ratio46.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-48.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-75.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M178ROI % (ttm)-116.7Gross Margin Increase y-yN

Gurus Latest Trades with RNN

Number of guru portfolios checked: 56.

No Entry found!

RNN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RNN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ahn Chang HoDirector 2014-06-12Sell136,193$0.99-28.28 view
Jeong Tae HeumCFO 2013-09-09Sell71,139$0.4654.35 view
Kivel RichardDirector 2011-10-03Buy2,500$1.04-31.73 view
Brandt Peter C.Director 2011-09-09Buy125,000$1.17-39.32 view
Brandt Peter C.Director 2011-09-07Buy25,000$0.96-26.04 view
Ahn Chang HoChairman & CEO, 10% Owner 2011-05-18Buy1,008,078$1.31-45.8 view
Ahn Chang HoChairman & CEO, 10% Owner 2011-04-01Buy320,846$1.22-41.8 view
McIntosh David MDirector 2009-07-30Buy5,600$0.8-11.25 view
Ahn Chang HoChairman & CEO, 10% Owner 2009-05-04Buy260,000$0.684.41 view
Ahn Chang HoChairman & CEO, 10% Owner 2009-05-04Sell2,600,000$0.684.41 view

Press Releases about RNN :

    Quarterly/Annual Reports about RNN:

    News about RNN:

    Articles On GuruFocus.com
    Weekly CEO Buys Highlight: RNN, IIG, FSC, GEO, DAN May 21 2011 
    Weekly CEO Buys Highlight: GBDC, EXL, RNN, KYN, CMTL Apr 09 2011 

    More From Other Websites
    Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid... Jul 18 2014
    Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid... Jul 18 2014
    What Falling Estimates & Price Mean for Rexahn Pharmaceuticals (RNN) Jun 16 2014
    REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2014
    Rexahn files $150M mixed securities shelf May 23 2014
    REXAHN PHARMACEUTICALS, INC. Financials May 21 2014
    Rexahn Pharmaceuticals (RNN) Jumps: Stock Surges 19.2% May 16 2014
    Rexahn sees cash, cash equivalents balance sufficient to fund company into 1H16 May 15 2014
    Rexahn reports Q1 EPS (9c), consensus (2c) May 15 2014
    Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results and Pipeline Update May 15 2014
    REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 14 2014
    Rexahn Pharmaceuticals: An Undervalued Oncology Play With Risk Diversification May 14 2014
    Rexahn announces additional RX-3117 preclinical studies data May 08 2014
    Rexahn Announces Additional Data from Preclinical Studies of RX-3117 May 08 2014
    Success Of Rexahn's Nano-Sized Taxotere Can Help Big Pharma Ease Patent Cliff Apr 21 2014
    Rexahn presents data from preclinical studies of RX-21101 Apr 21 2014
    Rexahn Presents Data from Preclinical Studies of RX-21101 Apr 21 2014
    Rexahn Pharmaceuticals to Present Data on RX-3117 and RX-21101 at the 2014 American Association for... Apr 02 2014
    Rexahn sees complete RX-3117 Phase I enrollment in 4Q14-early FY15 Mar 24 2014
    Rexahn Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent... Mar 24 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide